Related Experiment Video
Updated: May 20, 2026
Quantifying the Modulation of Elastase Enzyme Activity Through Colorimetric Analysis
Published on: January 17, 2025
Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer
Stefano Partelli1, Luca Frulloni, Consolato Minniti
1Department of Surgery, University of Verona, Policlinico GB Rossi, Verona, Italy.
Background:
The relationship between prognosis of advanced pancreatic cancer and exocrine secretion impairment is unknown.
Aim:
To investigate a possible correlation between faecal elastase-1 value and survival in advanced pancreatic cancer.
Methods:
194 patients with advanced pancreatic cancer were prospectively enrolled between 2007 and 2009 and underwent faecal elastase-1 measurement. Exocrine pancreatic secretion was defined as "moderately reduced" (faecal elastase-1: 100-200 μg/g), "severely reduced" (faecal elastase-1<100 and >20 μg/g) and "extremely reduced" (faecal elastase-1≤20 μg/g).
Results:
Median faecal elastase-1 was 204 μg/g (interquartile range 19; 489). Overall, 48 patients (25%) had an extremely reduced exocrine pancreatic secretion, 28 (14%) a severely reduced exocrine pancreatic secretion and 21 (11%) a moderately reduced exocrine pancreatic secretion. Patients with extremely reduced exocrine pancreatic secretion had higher rates of pancreatic head localizations (P<0.01) and of jaundice (P<0.01). Median overall survival was 10.5 months. Patients with faecal elastase-1≤20 μg/g had a worse prognosis (median survival: 7 versus 11 months, P=0.031). Presence of metastases (Hazard ratio 1.81, P<0.0001), haemoglobin ≤12 g/L (Hazard ratio 2.12, P=0.001), albumin ≤40 g/L (Hazard ratio 1.64, P=0.010) and FE-1≤20 μg/g (Hazard ratio 1.59 P=0.023) resulted as independent predictors of survival in advanced pancreatic cancer patients.
Conclusions:
A low value of faecal elastase-1 is strongly correlated with a poor survival in advanced pancreatic cancer.
